Moorestown, New Jersey, United States
biotecalpha™
February 23, 2026 Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
– Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma –
– FDA Accepted Anito-cel BLA for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma –
– Provides Gilead with Full Control of Anito-cel, Accelerating Development and Commercialization while Eliminating Profit-Share, Milestones, and Royalties –
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases.
Kite, a Gilead company, and Arcellx have an existing collaboration to co-develop and co-commercialize Arcellx’s lead pipeline candidate, anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for patients with multiple myeloma. Despite advancements in treatment, many patients with multiple myeloma eventually relapse and require additional lines of therapy. As disease progresses, patients often experience diminishing responses, increasing toxicity and fewer viable options, especially those who are heavily pretreated or unable to tolerate existing therapies.
7:00 AM February 9 2026 Announcement.pdf Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®
- Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting their health at risk
- Novo Nordisk takes decisive legal action to stop Hims’ illegal conduct, protect public health, and defend the scientific innovations that deliver better health outcomes to Americans living with serious chronic diseases like obesity and diabetes
- Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages
Plainsboro, NJ, US and Bagsværd, Denmark, February 9, 2026 – Novo Nordisk announced today that it has filed a lawsuit against telehealth company Hims & Hers (“Hims”), for infringing US Patent 8,129,343 with Hims’ compounded semaglutide products for the US market. Hims has engaged in promotional campaigns that highlight its compounded semaglutide products, duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs. This includes Hims’ recent launch, and two days later, abrupt discontinuance of its “Compounded GLP-1 Pill,” which came on the heels of Novo Nordisk’s introduction of the Wegovy® pill, the first and only FDA-approved GLP-1 pill for weight loss. Hims continues to unlawfully mass compound injectable versions, made with inauthentic API, and these knock-offs are putting patient health and wellbeing at risk.
Latest on compounded and counterfeit products and other important information about semaglutide
https://www.novomedlink.com/content/dam/novomedlink/semaglutide/02-05-2026-company-statement.pdf
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility January 30, 2026
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide
Company plans to create more than 2,800 manufacturing and construction jobs at Lilly's 10th U.S. manufacturing site announced since 2020
INDIANAPOLIS, Jan. 30, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania. The site will serve as Lilly's newest injectable medicine and device manufacturing facility that will produce next-generation weight-loss therapies, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone receptor agonist. This is the fourth new U.S. manufacturing site Lilly has announced since February 2025, as part of its commitment to bolster domestic medicine production.
Lilly will bring 850 high-value jobs to the area, including engineers, scientists, operations personnel and lab technicians. Construction, expected to begin in 2026, is anticipated to generate 2,000 construction jobs. The site will be operational in 2031.
AstraZeneca plans to invest $15 billion in China through 2030 to pioneer the next-generation of innovative medicines
PUBLISHED 29 January 2026
Landmark investment will expand AstraZeneca’s capabilities to discover, develop, and manufacture transformative new treatments in China
Investment will support delivery of AstraZeneca’s 2030 ambition
AstraZeneca today announced $15 billion investment in China through 2030 to expand medicines manufacturing and R&D. This investment will leverage the country’s scientific excellence, advanced manufacturing, and China-UK healthcare ecosystem collaborations to deliver cutting-edge treatments to patients across China and globally.
Keir Starmer, UK Prime Minister, said: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements. AstraZeneca’s expansion and leadership in China will help the British manufacturer continue to grow - supporting thousands of UK jobs. The multi-billion pound investment announced today from AstraZeneca, alongside partnerships from some of our country’s leading universities, furthers research and development in the UK which is helping to power our world class life sciences sector.”
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Today’s landmark investment of $15 billion begins an exciting next chapter for AstraZeneca in China, which has become a critical contributor to scientific innovation, advanced manufacturing, and global public health. By expanding our capabilities in breakthrough treatments like cell therapy and radioconjugates, we will strengthen our contribution to China’s high-quality development and, most importantly, bring next-generation modalities to patients.”
January 12, 2026 AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers
NORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy and in combination regimens across multiple advanced solid tumors.
Scientists are inventing treatments for devastating diseases. There’s just one problem. Genetic therapies could be used to treat hundreds of diseases. The path to patients is tricky. January 11, 2026 at 5:00 a.m. EST Today at 5:00 a.m. EST By Carolyn Y. Johnson
This past spring, a biotech company announced the first use of a new gene-editing technology in people to fix an errant gene that causes a severe immune disorder. In June, a baby born with a life-threatening metabolic disorder was allowed to leave the hospital after a six-month sprint by scientists to create a bespoke treatment for him. And increasingly, a generation of “bubble babies” born without immune defenses are nearing their teenage years after receiving a one-time experimental gene therapy in early childhood.
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management Wegovy® pill showed a mean weight loss of 16.6% in the OASIS 4 trial1 Wegovy® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse cardiovascular events* Novo Nordisk expects to launch Wegovy® pill in the US in early January 2026 Bagsværd, Denmark, 22 December 2025
Bagsværd, Denmark, 22 December 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events*.
The Wegovy® pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management. The approval is based on the OASIS trial programme and the SELECT trial2. In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated 16.6% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more comorbidities1. The weight loss achieved with the Wegovy® pill is similar to that of injectable Wegovy® 2.4 mg. Furthermore, one in three people experienced 20% or greater weight loss in the OASIS 4 trial1. The well-known safety and tolerability profile of semaglutide was reaffirmed with the Wegovy® pill in the OASIS-4 trial, which was comparable to previous trials with semaglutide for weight management.
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook December 19, 2025
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Millio
SAN RAFAEL, Calif., and PRINCETON, N.J., Dec. 19, 2025 /PRNewswire/ -- BioMarin Phan in Revenue Over Past Four Quarters
Provides Opportunity to Expand Access to Galafold and Pombiliti + Opfolda to Patients in New Markets Across BioMarin's Global Footprint; Pending U.S. Galafold Patent Litigation Resolved
Will Accelerate Revenue Growth Immediately After Close; Expected to be Accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the First 12 Months Post-Close and Substantially Accretive to Non-GAAP Diluted EPS Beginning in 2027
Conference Call Today at 8:15 a.m. Eastern Timermaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. The agreement has been unanimously approved by the Boards of Directors of both companies and Amicus' Board of Directors unanimously recommended that Amicus' stockholders vote to adopt the agreement. The transaction is expected to close in the second quarter of 2026, subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions.
To learn more, please visit the company's website at www.amicusrx.com.
‘Major breakthroughs’: Chinese biotech firms plan global expansions after domestic success Strong manufacturing base a driving force behind overseas expansion, but industry leaders and analysts say hurdles remain Alice Li Published: 2:00pm, 11 Dec 2025Updated: 3:36pm, 11 Dec 2025
China’s Health Care Costs Shift to Individuals as Government Share Shrinks Published: Dec. 4, 2025 11:44 a.m. GMT+8
China’s citizens are shouldering a growing share of the nation’s health care bill as government spending shrinks, while the country's hospital system consolidates around elite institutions, a trend that is emptying out smaller local providers and starting to slow growth at the very top.
November 18, 2025 Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
Arrivals of the twice-yearly PrEP option in Eswatini and Zambia mark an important milestone in the goal of ending the HIV epidemic in sub-Saharan Africa
FOSTER CITY, Calif. & MBABANE, Eswatini--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention options across sub-Saharan Africa, which is home to approximately two-thirds of all people living with HIV globally.
Princeton joins new cancer research hub launched with Weill Family Foundation gift By The Office of Communications on March 27, 2025, 9 a.m.
Princeton University is collaborating with The Rockefeller University, Weill Cornell Medicine and the Ludwig Institute for Cancer Research in a new East Coast hub dedicated to making immunotherapy more effective for cancer patients, an initiative launched with a $50 million gift from the Weill Family Foundation and to be matched with philanthropy from each partner institution that together will total more than $125 million.
Philanthropists Joan and Sanford I. Weill announced the new partnership in a press release today, together with leaders of the four institutions.
The Weill Cancer Hub East “connects world-class experts” from the four institutions to advance the promise of immunotherapy for cancer patients by examining “the interplay between nutrition, metabolism and immunotherapy,” the press release said.
“With the best minds in the field armed with the most advanced research techniques, the Weill Cancer Hub East will seek to elevate immunotherapy and improve patient care for people battling cancer,” Sanford “Sandy” Weill said in the press release. “Joan and I could not be more excited about the endless possibilities of this special partnership — investment in science and medicine is our labor of love.”
biotecalpha™
Can US health care solve its cost crisis by copying Europe? Arthur Sullivan 11/27/2025 The US spends more per capita on health than any other country and health care is vastly more expensive for citizens than anywhere else. Can it learn anything from European systems? The steep cost of health care remains a thorny political issue in the United States. Disagreement over the extension of health care subsidies was at the center of the recent 43-day government shutdown. And President Donald Trump's approval ratings have been severely hit by cost of living concerns, including on the soaring cost of health care.
Lilly announces plans to open Lilly Gateway Labs site in Philadelphia November 19, 2025 Gateway Labs model provides lab space and tailored scientific engagement to fuel next-generation medicines New Center City site, in partnership with Breakthrough Properties, will host a select group of early-stage biotech companies INDIANAPOLIS, Nov. 19, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to open a new Lilly Gateway Labs (LGL) site in Philadelphia, bringing its distinctive model of scientific partnership to a city known for shaping the future of medicine.
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans November 6, 2025 Download PDF Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. The agreement builds on Lilly's longstanding commitment to finding solutions with policymakers that improve access to life-changing medicines. In 2020, Lilly partnered with the Trump Administration on a pilot program that paved the way for Lilly to be the first company to cap out-of-pocket insulin costs at $35 per month. Lilly will now improve access to nearly 40 million Americans living with obesity on government insurance programs and millions more who pay out-of-pocket. Unlocking access to these medicines can be game-changing for American
01:01 6 November 2025 Announcement.pdf Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost Obesity medicines coverage in U.S. Medicare Part D via a pilot programme, starting during 2026 Introduction of lower prices for Novo Nordisk’s semaglutide medicines in U.S. Medicare Part D and Medicaid and in direct-to-patients cash channel Novo Nordisk currently expects an estimated negative low single-digit impact on global sales growth in 2026 Bagsværd, Denmark, 6 November 2025 – Today it was announced that Novo Nordisk has agreed with the U.S. Administration to lower drug prices beginning in 2026 and expand patient access and affordability for semaglutide medicines, including Wegovy® and Ozempic®, in U.S. Medicare Part D and Medicaid and in direct-to-patient cash channel. Medicare Part D coverage for anti-obesity medicines will be enabled through a pilot program designed to cover a majority of Part D beneficiaries. In addition, No
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide November 3, 2025 Download PDF Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain INDIANAPOLIS, Nov. 3, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain.
Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients October 28, 2025
September 3, 2025 Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy New Bay Area Building Marks Significant Progress as Part of $32 Billion U.S. Investment Projected to Create $43 Billion in Economic Value FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters. This milestone marks continued momentum in Gilead’s multi-year strategy to drive growth and scientific leadership across virology, oncology, and inflammation, increasingly built on growing biologics capabilities. It is part of Gilead’s planned $32 billion investment in U.S. innovation through 2030. This investment is projected to generate more than $43 billion in economic value nationwide, strengthening America’s biopharmaceutical leadership while fueling high-quality jobs, re
Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S. Save November 3, 2025 6:45 am EST Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country RAHWAY, N.J.--(BUSINESS WIRE)-- The Merck Foundation announced today the launch of the Collaborative for Equity in Cardiac Care, a $22 million, five-year initiative aimed at enhancing access to high-quality, person-centered health care for people living with heart conditions in the U.S. Eleven organizations are receiving grants to support the development and implementation of evidence-informed, comprehensive programs to improve health outcomes in communities where access to timely care for cardiovascular disease is a challenge.
September 30, 2025 AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S. Open a printable version of this pageEmail the URL of this page to a friend Expansion increases biologics manufacturing for immunology and oncology medicines Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing Furthers longstanding commitment to AbbVie's Massachusetts sites and workforce NORTH CHICAGO, Ill., Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass., which serves as a center of excellence for biologics research and development and manufacturing. This expansion is part of the company's previously announced commitment to invest more than $10 billion of capital in the U.S. to broadly support innovation and expand critical biologics manufacturing capabilities and capacity.
AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs THOUSAND OAKS, Calif., Sept. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to invest more than $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California. The center is designed to bring together researchers, engineers and scientists across disciplines to enhance collaboration and accelerate the discovery of next-generation therapeutics for patients with the most serious diseases. The building will feature advanced automation and digital capabilities, empowering scientists with the tools and environment needed to drive scientific excellence and advancements in biotechnology.
China’s southwestern industrial base eyes breakthroughs on novel drugs As country pushes for scientific and technological self-reliance, Chongqing will provide support for pharmaceutical research and development Xinyi Wuin Beijing Published: 4:00pm, 7 Nov 2025Updated: 5:15pm, 7 Nov 2025 Chongqing, a key economic hub in southwest China, has unveiled a plan to support the development of innovative drugs as the country steps up its push for scientific and technological self-reliance.